You just read:

Janssen Reports Positive Top-line Phase 3 Study Results of Investigational, Long-acting Injectable HIV Treatment Regimen Administered Every Two Months

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Aug 22, 2019, 02:02 ET